Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
Sponsor: The Affiliated Hospital of Hangzhou Normal University
Summary
To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.
Official title: Prospective Cohort Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2023-11-18
Completion Date
2026-12-31
Last Updated
2023-11-18
Healthy Volunteers
No
Interventions
Pioglitazone metformin tablets
Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
Other drugs
Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
Drug-free
Drug-free